PTN Company Profile and Key Details

Q: Who are the executives of PTN?

Burns McClellanVice President of Investor RelationsDr. Carl Spana Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorDr. Michael B. Raizman M.D.Chief Medical OfficerMr. Robert JordanSenior Vice President of Program OperationsMr. James E. HattersleySenior Vice President of Bus. Devel.Mr. John Dodd Ph.D.Senior Vice President of Preclinical Devel.Mr. Stephen A. Slusher Esq.Chief Legal Officer

AMEX : PTN

Palatin Technologies

$21.55

-0.235-1.08%

Open: 11:44 AM

67.49

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Palatin Technologies, Inc. (PTN) stock declined over -1.08%, trading at $21.55 on AMEX, down from the previous close of $21.79. The stock opened at $21.50, fluctuating between $21.50 and $21.89 in the recent session.

Stock Snapshot

21.785

Prev. Close

560.42M

Market Cap

21.5

Day Low

-13.99

P/E Ratio

-1.54

EPS (TTM)

-1.96

Cash Flow per Share

21.5

Open

26.01M

Number of Shares

21.89

Day High

90.49%

Free Float in %

-0.81

Book Value

2.48K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	18.58	20.85	18.50	20.49	42.24K
Apr 13, 2026	17.29	19.40	17.29	18.51	20.21K
Apr 10, 2026	19.40	19.40	17.95	18.02	6.06K
Apr 09, 2026	18.50	18.96	18.35	18.35	14.77K
Apr 08, 2026	19.40	19.40	18.65	19.40	11.76K
Apr 07, 2026	19.40	19.40	18.50	19.00	25.36K
Apr 06, 2026	18.22	19.00	18.01	18.03	10.43K
Apr 02, 2026	18.00	18.01	17.50	17.72	16.43K
Apr 01, 2026	17.70	18.50	17.20	17.20	13.58K
Mar 31, 2026	18.35	19.06	17.02	17.42	9.77K
Mar 30, 2026	20.00	20.01	17.32	18.55	23.6K
Mar 27, 2026	20.59	20.61	19.51	19.99	9.58K
Mar 25, 2026	20.50	21.29	20.45	21.00	10.22K
Mar 24, 2026	20.75	20.94	19.85	19.85	4.88K
Mar 23, 2026	20.80	21.80	19.50	20.59	7.33K
Mar 20, 2026	23.34	23.45	21.06	21.45	32.39K
Mar 19, 2026	20.77	21.41	20.56	20.56	3.05K
Mar 18, 2026	23.64	23.64	21.48	21.48	11.13K
Mar 17, 2026	23.20	23.25	22.59	23.23	11.02K
Mar 16, 2026	23.50	23.50	22.19	22.52	11.68K

Contact Details

Cranbury, NJ 08512

United States

https://palatin.com 609 495 2200

About Company

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Stock Peers

TBXU

0.7952+2.49%

Direxion Daily Biotech Top 5 Bull 2X ETF$32.75 PTHS

Pelthos Therapeutics Inc.$23.00 ARMP

1.19+10.18%

Armata Pharmaceuticals, Inc.$12.88 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.19+2.72%

NeurAxis, Inc.$7.18 CVM

0.34+8.46%

CEL-SCI Corporation$4.36 CANF

0.13+4.45%

Can-Fite BioPharma Ltd.$3.05 PLX

0.07+3.06%

Protalix BioTherapeutics, Inc.$2.36 NSRX

-0.08-3.43%

Nasus Pharma Ltd.$2.25

Company Overview

Palatin Technologies, Inc. (AMEX:PTN) closed at $21.55 USD, losing -$0.23 (-1.08%) from the previous close of $21.79. The stock is currently mid-range between its 52-week high and low $2.00 and $31.00. With a market capitalization of about $560.42 million, Palatin Technologies, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 19.25 thousand shares, volume is running light vs its 52-week average. Headquartered in Cranbury, NJ, Palatin Technologies, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carl Spana, the company employs approximately 30 people and listed since October 15, 1997. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

Technical Performance

PTN has shown sold momentum, gaining 14.43% over the past week and 138.44% over the past quarter, though year-to-date performance is up 9.3%. Short-term trend indicators are bearishly aligned (SMA20 15.31%, SMA50 18.47%, SMA200 83.58%). The stock’s 14-day RSI is 60.34 (firm momentum), while the ATR of 2.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.15% below its high and over 1099.43% above its low. Average 10-day trading volume of 18.69 thousand shares is in line with the 3-month average of 19.69 thousand, indicating normal recent market interest.

Valuation Metrics

Palatin Technologies, Inc. trades at a P/E ratio of -2.01, slightly below the S&P 500 average, with a price-to-sales ratio of 57.88 and a price-to-book ratio of 1.69 suggesting the stock is closer to book value. The P/FCF stands at -32.67, also below market averages.

Dividend & Fair Value

Palatin Technologies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.46. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Palatin Technologies, Inc. generated EPS of -$10.13 over the past year. Five-year average earnings growth is 23.09%. Wall Street analysts project EPS growth of 54.06% annually over the next five years. The latest quarter delivered EPS of -$4.14. The next quarter is forecast at -$1.24. Next year's EPS is expected at $77.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $60.00. The high target offers 192.83% upside. The low target suggests 192.83% downside. The mean target is $60.00. This offers 192.83% upside. Palatin Technologies, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended September 23, 2025, missed forecasts by -56.4%. The prior quarter beat by 211.76%. Over the last six quarters, Apple has recorded several small beats. These include -10.91% in September 30, 2024.

Shareholding & Insider Activity

Palatin Technologies, Inc. has 26.01 million shares outstanding. The public float is 23.53 million shares, elevated short interest at 31.28% of float. This equals 8.00 million shares. The short ratio is 8.58 days. Institutional investors hold 14.6% of the float. Insiders own 2.63%. MARXE AUSTIN W & GREENHOUSE DAVID M holds 1.80 million shares, SPANA CARL has 1.67 million shares and Hull Joseph Stanley has 775.97 thousand shares. Over the past six months, insider transactions show net selling. They sold 565.00 shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Palatin Technologies has not generated any revenue. Returns are negative, with ROA at -529.77% and ROE at 362.30%.
On valuation metrics, Palatin Technologies trades at a P/E of -2.01, P/S of 57.88 and P/B of 1.69. The current ratio is 2.76 and quick ratio is 2.76. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -29472.47 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -45.50.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Palatin Technologies posted revenue of $0.00, down slightly from $4.49M in the prior quarter. Gross profit was - $258.92K (margin 0.00%). Operating income was - $22.71M (margin 0.0%). Net income was- $17.31M (EPS - $32.15).
The company ended the quarter with $2.56M in cash and short-term investments, a total debt of $163.78K, and net debt of - $2.40M. Total assets were $3.27M, with equity of - $4.78M. Financials further reflected weakness, with operating cash flow of - $21.31M, free cash flow of - $21.31M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Palatin Technologies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.79%, with price expected at $17.46 by April 28, 2026, within a range of $16.28 to $18.74 3-Month Outlook: Projected rise of 20.11%, reaching $24.61 by July 13, 2026, with a range of $24.27 to $24.94. 1-Year Outlook: Projected gain of 7.08%, with price at $21.94 by April 14, 2027, within a range of $19.64 to $23.37.

Key Takeaways

Palatin Technologies, Inc. (AMEX:PTN) shares are flat 9.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Palatin Technologies, Inc. trading at a premium to the broader market with a P/E of -2.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $33.04, suggesting 61.25% upside. Our AI forecast model points to short-term weakness (-14.79% over two weeks), a medium-term rise (20.11% over three months), and a longer-term gain (7.08% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Palatin Technologies, Inc. (PTN) stock price?

Palatin Technologies, Inc. (AMEX: PTN) stock price is $21.55 in the last trading session. During the trading session, PTN stock reached the peak price of $21.89 while $21.50 was the lowest point it dropped to. The percentage change in PTN stock occurred in the recent session was -1.08% while the dollar amount for the price change in PTN stock was - $0.24.

PTN's industry and sector of operation?

The AMEX listed PTN is part of Biotechnology industry that operates in the broader Healthcare sector. Palatin Technologies, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PTN?

Burns McClellan
Vice President of Investor Relations
Dr. Carl Spana Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Michael B. Raizman M.D.
Chief Medical Officer
Mr. Robert Jordan
Senior Vice President of Program Operations
Mr. James E. Hattersley
Senior Vice President of Bus. Devel.
Mr. John Dodd Ph.D.
Senior Vice President of Preclinical Devel.
Mr. Stephen A. Slusher Esq.
Chief Legal Officer

How PTN did perform over past 52-week?

PTN's closing price is 924.5% higher than its 52-week low of $2.00 where as its distance from 52-week high of $31.00 is -33.9%.

How many employees does PTN have?

Number of PTN employees currently stands at 30.

Link for PTN official website?

Official Website of PTN is: https://palatin.com

How do I contact PTN?

PTN could be contacted at phone 609 495 2200 and can also be accessed through its website. PTN operates from Cedar Brook Corporate Center, Cranbury, NJ 08512, United States.

How many shares of PTN are traded daily?

PTN stock volume for the day was 2.48K shares. The average number of PTN shares traded daily for last 3 months was 19.25K.

What is the market cap of PTN currently?

The market value of PTN currently stands at $560.42M with its latest stock price at $21.55 and 26.01M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	30
Beta	0.94
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

PTN Company Profile and Key Details

Palatin Technologies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook